Seven Eight Capital LP Buys Shares of 106,894 Teladoc Health, Inc. (NYSE:TDOC)

Seven Eight Capital LP purchased a new stake in shares of Teladoc Health, Inc. (NYSE:TDOC) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 106,894 shares of the health services provider’s stock, valued at approximately $1,045,000. Seven Eight Capital LP owned 0.06% of Teladoc Health as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. ICA Group Wealth Management LLC bought a new stake in Teladoc Health during the fourth quarter valued at approximately $28,000. Principal Securities Inc. bought a new stake in shares of Teladoc Health during the 4th quarter valued at $45,000. Signaturefd LLC increased its stake in shares of Teladoc Health by 148.7% in the 2nd quarter. Signaturefd LLC now owns 2,868 shares of the health services provider’s stock worth $28,000 after purchasing an additional 1,715 shares in the last quarter. International Assets Investment Management LLC bought a new position in Teladoc Health in the 2nd quarter worth $29,000. Finally, SageView Advisory Group LLC purchased a new position in Teladoc Health during the first quarter valued at $48,000. Hedge funds and other institutional investors own 76.82% of the company’s stock.

Insiders Place Their Bets

In other news, insider Vidya Raman-Tangella sold 3,857 shares of the firm’s stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $8.14, for a total value of $31,395.98. Following the completion of the sale, the insider now directly owns 33,667 shares of the company’s stock, valued at approximately $274,049.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Vidya Raman-Tangella sold 3,857 shares of the stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $8.14, for a total value of $31,395.98. Following the sale, the insider now owns 33,667 shares of the company’s stock, valued at $274,049.38. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Laizer Kornwasser sold 10,879 shares of the firm’s stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $8.14, for a total transaction of $88,555.06. Following the completion of the sale, the chief executive officer now owns 99,929 shares of the company’s stock, valued at approximately $813,422.06. The disclosure for this sale can be found here. Insiders have sold 57,819 shares of company stock valued at $442,204 over the last ninety days. 0.95% of the stock is owned by insiders.

Teladoc Health Trading Down 4.5 %

TDOC stock opened at $8.77 on Friday. The firm has a market cap of $1.50 billion, a PE ratio of -6.17 and a beta of 0.90. The firm has a fifty day moving average price of $8.05 and a 200 day moving average price of $10.95. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.62 and a current ratio of 1.66. Teladoc Health, Inc. has a fifty-two week low of $6.76 and a fifty-two week high of $22.54.

Teladoc Health (NYSE:TDOC) last posted its earnings results on Wednesday, July 31st. The health services provider reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.08. Teladoc Health had a negative net margin of 38.54% and a negative return on equity of 10.25%. The firm had revenue of $642.44 million for the quarter, compared to the consensus estimate of $649.34 million. Sell-side analysts anticipate that Teladoc Health, Inc. will post -1.18 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Barclays decreased their price objective on Teladoc Health from $20.00 to $10.00 and set an “overweight” rating on the stock in a research note on Thursday, August 1st. Stifel Nicolaus decreased their target price on shares of Teladoc Health from $16.00 to $9.00 and set a “hold” rating on the stock in a research note on Thursday, August 1st. Oppenheimer dropped their price target on shares of Teladoc Health from $21.00 to $17.00 and set an “outperform” rating for the company in a research report on Thursday, August 1st. Jefferies Financial Group raised their price objective on shares of Teladoc Health from $8.00 to $10.00 and gave the company a “hold” rating in a research report on Tuesday. Finally, Evercore ISI lowered their target price on shares of Teladoc Health from $14.00 to $10.00 and set an “in-line” rating on the stock in a research note on Tuesday, July 9th. Fifteen analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, Teladoc Health has a consensus rating of “Hold” and an average target price of $12.31.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.